REV3L and cervical cancer: In this study, we found that inhibition of REV3L increased cellular sensitivity to cisplatin with activation of the mitochondrial apoptotic pathway in cervical cancer cells, with altered Bcl-2, Bcl-xl, and Bax expression levels.